These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 22629725)

  • 1. [UDCA in the treatment of nonalcoholic fatty liver disease].
    Grigor'eva IN
    Eksp Klin Gastroenterol; 2011; (11):79-85. PubMed ID: 22629725
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [UDCA in the treatment of nonalcoholic fatty liver disease].
    Grigor'eva IN
    Eksp Klin Gastroenterol; 2011; (9):125-31. PubMed ID: 22629789
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ursodeoxycholic acid improves insulin sensitivity and hepatic steatosis by inducing the excretion of hepatic lipids in high-fat diet-fed KK-Ay mice.
    Tsuchida T; Shiraishi M; Ohta T; Sakai K; Ishii S
    Metabolism; 2012 Jul; 61(7):944-53. PubMed ID: 22154323
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of NASH with ursodeoxycholic acid: cons.
    Liechti F; Dufour JF
    Clin Res Hepatol Gastroenterol; 2012 Sep; 36 Suppl 1():S46-52. PubMed ID: 23141894
    [TBL] [Abstract][Full Text] [Related]  

  • 5. miR-34a/SIRT1/p53 is suppressed by ursodeoxycholic acid in the rat liver and activated by disease severity in human non-alcoholic fatty liver disease.
    Castro RE; Ferreira DM; Afonso MB; Borralho PM; Machado MV; Cortez-Pinto H; Rodrigues CM
    J Hepatol; 2013 Jan; 58(1):119-25. PubMed ID: 22902550
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of ursodeoxycholic acid in non-alcoholic steatohepatitis: a systematic review.
    Xiang Z; Chen YP; Ma KF; Ye YF; Zheng L; Yang YD; Li YM; Jin X
    BMC Gastroenterol; 2013 Sep; 13():140. PubMed ID: 24053454
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Omega-3 polyunsaturated fatty acid and ursodeoxycholic acid have an additive effect in attenuating diet-induced nonalcoholic steatohepatitis in mice.
    Kim JK; Lee KS; Lee DK; Lee SY; Chang HY; Choi J; Lee JI
    Exp Mol Med; 2014 Dec; 46(12):e127. PubMed ID: 25523099
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial.
    Lindor KD; Kowdley KV; Heathcote EJ; Harrison ME; Jorgensen R; Angulo P; Lymp JF; Burgart L; Colin P
    Hepatology; 2004 Mar; 39(3):770-8. PubMed ID: 14999696
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of NASH with ursodeoxycholic acid: pro.
    Ratziu V
    Clin Res Hepatol Gastroenterol; 2012 Sep; 36 Suppl 1():S41-5. PubMed ID: 23141893
    [TBL] [Abstract][Full Text] [Related]  

  • 10. UDCA for NASH: end of the story?
    Haedrich M; Dufour JF
    J Hepatol; 2011 May; 54(5):856-8. PubMed ID: 21145815
    [No Abstract]   [Full Text] [Related]  

  • 11. Ursodeoxycholic acid ameliorates hepatic lipid metabolism in LO2 cells by regulating the AKT/mTOR/SREBP-1 signaling pathway.
    Hu J; Hong W; Yao KN; Zhu XH; Chen ZY; Ye L
    World J Gastroenterol; 2019 Mar; 25(12):1492-1501. PubMed ID: 30948912
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ursodeoxycholic acid treatment of hepatic steatosis: a (13)C NMR metabolic study.
    Nunes PM; Jones JG; Rolo AP; Palmeira CM; Carvalho RA
    NMR Biomed; 2011 Nov; 24(9):1145-58. PubMed ID: 21538633
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of ursodeoxycholic acid on hepatic steatosis in rats.
    Okan A; Astarcioglu H; Tankurt E; Sagol O; Altekin E; Astarcioglu I; Gonen O
    Dig Dis Sci; 2002 Nov; 47(11):2389-97. PubMed ID: 12452368
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapy for nonalcoholic fatty liver disease.
    Moseley RH
    J Clin Gastroenterol; 2008 Apr; 42(4):332-5. PubMed ID: 18277910
    [No Abstract]   [Full Text] [Related]  

  • 15. Ursodeoxycholyl lysophosphatidylethanolamide improves steatosis and inflammation in murine models of nonalcoholic fatty liver disease.
    Pathil A; Mueller J; Warth A; Chamulitrat W; Stremmel W
    Hepatology; 2012 May; 55(5):1369-78. PubMed ID: 22183915
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ursodesoxycholic acid is an FFA4 agonist and reduces hepatic steatosis via FFA4 signaling.
    Xu F; Wang J; Wang P; Hou T; Zhou H; Zhao Y; Wang J; Liu Y; Liang X
    Eur J Pharmacol; 2022 Feb; 917():174760. PubMed ID: 35033554
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of ursodeoxycholic acid therapy on carotid intima media thickness, apolipoprotein A1, apolipoprotein B, and apolipoprotein B/A1 ratio in nonalcoholic steatohepatitis.
    Ozel Coskun BD; Yucesoy M; Gursoy S; Baskol M; Yurci A; Yagbasan A; Doğan S; Baskol G
    Eur J Gastroenterol Hepatol; 2015 Feb; 27(2):142-9. PubMed ID: 25533429
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized placebo-controlled trial of ursodeoxycholic acid with vitamin e in nonalcoholic steatohepatitis.
    Dufour JF; Oneta CM; Gonvers JJ; Bihl F; Cerny A; Cereda JM; Zala JF; Helbling B; Steuerwald M; Zimmermann A;
    Clin Gastroenterol Hepatol; 2006 Dec; 4(12):1537-43. PubMed ID: 17162245
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is vitamin e or ursodeoxycholic acid a valid treatment option for nonalcoholic fatty liver disease in 2016?
    Beaton MD; Al-Judaibi B
    Saudi J Gastroenterol; 2016; 22(3):169-70. PubMed ID: 27184632
    [No Abstract]   [Full Text] [Related]  

  • 20. Effects of ursodeoxycholic acid in combination with vitamin E on adipokines and apoptosis in patients with nonalcoholic steatohepatitis.
    Balmer ML; Siegrist K; Zimmermann A; Dufour JF
    Liver Int; 2009 Sep; 29(8):1184-8. PubMed ID: 19422479
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.